Organon shares jump on renewed takeover chatter tied to a reported Sun Pharma bid

Organon & Co. (OGN) is up 28.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears primarily driven by fresh M&A speculation after reports that India’s Sun Pharmaceutical Industries is preparing (or advancing) an all-cash bid for Organon valuing the company at roughly $13 billion. With Organon’s equity value well below that implied headline figure, any credible-sounding update can quickly reprice the stock as investors handicap a potential takeout premium.

Details:

Market reports on April 24, 2026 tied Organon’s sharp rally to a rumored binding, all-cash offer from Sun Pharma around the $13 billion level.

The same reporting framed the situation as a contested process, with other suitors (including large financial and strategic buyers) also mentioned as potential competitors.

Earlier in April, similar takeover talk pushed OGN sharply higher, while Sun Pharma had also publicly characterized prior market speculation as non-material/speculative at that time, keeping uncertainty high.

This kind of rumor-driven session often coincides with elevated volume and short-covering, which can amplify one-day percentage moves (speculation).

Sources:

Yahoo Finance, Moneycontrol, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$OGN Insider Trading Activity

$OGN insiders have traded $OGN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $OGN stock by insiders over the last 6 months:

CARRIE SMITH COX (Executive Chair) purchased 65,400 shares for an estimated $501,755

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive OGN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$OGN Hedge Fund Activity

We have seen 181 institutional investors add shares of $OGN stock to their portfolio, and 363 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AQR CAPITAL MANAGEMENT LLC added 4,394,814 shares (+105.2%) to their portfolio in Q4 2025, for an estimated $31,510,816
MILLENNIUM MANAGEMENT LLC removed 4,066,587 shares (-89.8%) from their portfolio in Q4 2025, for an estimated $29,157,428
SIO CAPITAL MANAGEMENT, LLC added 3,421,765 shares (+inf%) to their portfolio in Q4 2025, for an estimated $24,534,055
NORDEA INVESTMENT MANAGEMENT AB removed 3,086,456 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,129,889
D. E. SHAW & CO., INC. added 2,895,864 shares (+590.0%) to their portfolio in Q4 2025, for an estimated $20,763,344
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 2,619,936 shares (-27.6%) from their portfolio in Q4 2025, for an estimated $18,784,941
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,384,507 shares (-74.8%) from their portfolio in Q4 2025, for an estimated $17,096,915

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$OGN Price Targets

Multiple analysts have issued price targets for $OGN recently. We have seen 3 analysts offer price targets for $OGN in the last 6 months, with a median target of $9.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $8.0 on 02/24/2026
Terence Flynn from Morgan Stanley set a target price of $9.0 on 11/11/2025
Chris Schott from JP Morgan set a target price of $12.0 on 11/11/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.